This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The principle used in the analysis of effectiveness was treatment completers only. The primary health outcome measure was the category of blood cultures (positive, negative, or contaminant). The type of organisms grown in positive cases was reported. In this study the sample of patients also served as the control group.
Effectiveness results
A total of 5 patients (2.1%; 95% CI: 0.67 -4.74) had positive results. The corresponding figure for contaminated cultures was 13 (5.4%; 95% CI: 2.88 -8.97). The patients with positive results had a lower mean age (26 versus 75 months, p<0.01) and higher mean BNR (0.32 versus 0.07, p<0.001). Streptococcus and staphylococcus organisms were identified as present in positive cases and there were no cases of H. influenzae.
Clinical conclusions
Positive blood cultures were uncommon and were seen only in association with active varicella or underlying soft-tissue infections (osteomyelitis, septic arthritis). Blood cultures were twice as likely to be contaminated than positive. The small number of bacteremic patients precludes definitive statements about the prospective use of the complete blood count or BNR to predict bacteremia.
Measure of benefits used in the economic analysis
The number (percentage) of patients with cellulitis in each category of blood cultures was implicitly considered as the main benefit measure.
Direct costs
Discounting was not required due to the short time frame involved. Quantities were not reported separately from the costs. The cost analysis covered the costs of aerobic culture, anaerobic culture, sensitivity for positive blood culture, and repeat cultures. Charges were used instead of true costs. The perspective adopted in the cost analysis was not explicitly specified. Actual charge data from the study hospital were used in the cost analysis. The date of the price data was not stated.
Indirect Costs
Not considered.
Currency

US dollars ($).
Sensitivity analysis
No sensitivity analysis was performed.
Estimated benefits used in the economic analysis
The numbers of patients with negative, contaminated, and positive blood cultures were 225, 13, and 5, respectively. If the comparator (having a BNR=0.20 to be sent for blood culture) had been applied, a total of 213 patients (88%) could have avoided blood culture, while one case of positive culture would have been missed.
Cost results
The policy of obtaining blood cultures had a cumulated charge of $50,986. The estimated savings due to the hypothetical application of the comparator was $42,850.
